Mobocertinib: Mechanism of action, clinical, and translational science

• Κύριοι συγγραφείς: Michael J. Hanley (Συγγραφέας), D. Ross Camidge (Συγγραφέας), Robert J. Fram (Συγγραφέας), Neeraj Gupta (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Wiley, 2024-03-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Abstract Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations represent ~6%-12% of all EGFR‐mutated non‐small cell lung cancer (NSCLC) cases. First‐, second‐, and third‐generation tyrosine kinase inhibitors (TKIs) have limited clinical activity against EGFR ex20ins mutations...